Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next.
作者信息
Jiang Tao, Zhou Caicun, Hu Jie, Song Yuanlin
机构信息
Department of Medical Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China.
Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
出版信息
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S447-S450. doi: 10.21037/tlcr.2019.11.10.
Abstract
摘要
相似文献
1
Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next.晚期非小细胞肺癌中免疫检查点抑制剂与铂类化疗联合应用：已知情况与未来展望
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S447-S450. doi: 10.21037/tlcr.2019.11.10.
2
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?检查点阻断作为癌症治疗的发展：现状如何，未来如何？
Curr Opin Immunol. 2015 Apr;33:23-35. doi: 10.1016/j.coi.2015.01.006. Epub 2015 Jan 23.
3
Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?免疫疗法取代化疗用于晚期非小细胞肺癌的一线治疗：接下来会怎样？
J Thorac Dis. 2017 May;9(5):E519-E521. doi: 10.21037/jtd.2017.03.155.
4
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
5
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.化疗联合免疫检查点抑制剂用于晚期非小细胞肺癌患者一线治疗的系统评价和基于文献的Meta分析
Front Oncol. 2019 Apr 16;9:264. doi: 10.3389/fonc.2019.00264. eCollection 2019.
6
Chemotherapy for Stage IV Non-Small Cell Lung Cancer: Protocol Versus Nonprotocol? Is Noninvestigational Treatment Worthwhile? Patient Selection? Which Regimen? What's Next?IV期非小细胞肺癌的化疗：方案治疗与非方案治疗？非研究性治疗是否值得？患者选择？哪种方案？接下来是什么？
Semin Radiat Oncol. 1996 Apr;6(2):110-117. doi: 10.1053/SRAO00600110.
7
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
8
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
9
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.免疫检查点抑制剂：非小细胞肺癌治疗的新前沿。
Onco Targets Ther. 2016 Aug 16;9:5101-16. doi: 10.2147/OTT.S111209. eCollection 2016.
10
Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.针对具有野生型表皮生长因子受体（EGFR）的晚期非小细胞肺癌（NSCLC）患者的靶向治疗：新进展与充分性
Chin J Cancer. 2015 Jul 18;34(7):310-9. doi: 10.1186/s40880-015-0036-4.
引用本文的文献
1
Deciphering pathogenic cellular module at single-cell resolution in checkpoint inhibitor-related pneumonitis.解析免疫检查点抑制剂相关肺炎中单细胞分辨率下的致病细胞模块。
Oncogene. 2023 Oct;42(42):3098-3112. doi: 10.1038/s41388-023-02805-4. Epub 2023 Aug 31.
2
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance.一种克服基于谷胱甘肽的奥沙利铂耐药性的铂（IV）前药策略。
Commun Chem. 2022 Apr 6;5(1):46. doi: 10.1038/s42004-022-00661-z.
3
Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis.阿特珠单抗联合卡铂和白蛋白紫杉醇与卡铂和白蛋白紫杉醇用于中国、未经治疗的、IV 期、非鳞状、非小细胞肺癌患者的治疗：一项回顾性分析。
Pharmacol Res Perspect. 2022 Jun;10(3):e00941. doi: 10.1002/prp2.941.
4
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.评估替雷利珠单抗联合化疗对未经治疗的非鳞状非小细胞肺癌患者健康相关生活质量结局的影响。
Cancer J. 2022;28(2):96-104. doi: 10.1097/PPO.0000000000000583.
5
IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer.IMbrave 151：一项关于阿替利珠单抗联合贝伐单抗及化疗治疗晚期胆管癌患者的随机II期试验。
Ther Adv Med Oncol. 2021 Jul 31;13:17588359211036544. doi: 10.1177/17588359211036544. eCollection 2021.
6
Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience.肺癌患者中检查点抑制剂相关肺炎的临床类型：一项多中心经验
Transl Lung Cancer Res. 2021 Jan;10(1):415-429. doi: 10.21037/tlcr-20-1258.
7
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.基因组变异、肿瘤突变负荷及PD-L1表达在接受免疫治疗的晚期肺鳞状细胞癌中的预测价值。
Transl Lung Cancer Res. 2020 Dec;9(6):2367-2379. doi: 10.21037/tlcr-20-1130.
8
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment.骨髓来源细胞在化疗处理的肿瘤微环境中的双重作用
J Clin Med. 2020 Dec 2;9(12):3912. doi: 10.3390/jcm9123912.
本文引用的文献
1
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.晚期肺癌中不断演变的免疫肿瘤格局：非小细胞肺癌的一线治疗
Ther Adv Med Oncol. 2019 Aug 28;11:1758835919870360. doi: 10.1177/1758835919870360. eCollection 2019.
2
Tumor neoantigens: from basic research to clinical applications.肿瘤新生抗原：从基础研究到临床应用。
J Hematol Oncol. 2019 Sep 6;12(1):93. doi: 10.1186/s13045-019-0787-5.
3
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors.实体瘤免疫检查点免疫治疗的现有和新兴生物标志物。
Adv Ther. 2019 Oct;36(10):2638-2678. doi: 10.1007/s12325-019-01051-z. Epub 2019 Aug 13.
4
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
5
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.低剂量阿帕替尼优化肿瘤微环境并增强 PD-1/PD-L1 阻断在肺癌中的抗肿瘤作用。
Cancer Immunol Res. 2019 Apr;7(4):630-643. doi: 10.1158/2326-6066.CIR-17-0640. Epub 2019 Feb 12.
6
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.联合免疫检查点抑制剂和化疗增强实体瘤的抗肿瘤反应。
Ann Oncol. 2019 Feb 1;30(2):219-235. doi: 10.1093/annonc/mdy551.
7
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
8
The hallmarks of successful anticancer immunotherapy.成功的抗癌免疫疗法的特征。
Sci Transl Med. 2018 Sep 19;10(459). doi: 10.1126/scitranslmed.aat7807.
9
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
10
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
Zotero 插件